Literature DB >> 20018665

Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Christopher R Kimberlin1, Zachary A Bornholdt, Sheng Li, Virgil L Woods, Ian J MacRae, Erica Ollmann Saphire.   

Abstract

Ebolavirus causes a severe hemorrhagic fever and is divided into five distinct species, of which Reston ebolavirus is uniquely nonpathogenic to humans. Disease caused by ebolavirus is marked by early immunosuppression of innate immune signaling events, involving silencing and sequestration of double-stranded RNA (dsRNA) by the viral protein VP35. Here we present unbound and dsRNA-bound crystal structures of the dsRNA-binding domain of Reston ebolavirus VP35. The structures show that VP35 forms an unusual, asymmetric dimer on dsRNA binding, with each of the monomers binding dsRNA in a different way: one binds the backbone whereas the other caps the terminus. Additional SAXS, DXMS, and dsRNA-binding experiments presented here support a model of cooperative dsRNA recognition in which binding of the first monomer assists binding of the next monomer of the oligomeric VP35 protein. This work illustrates how ebolavirus VP35 could mask key recognition sites of molecules such as RIG-I, MDA-5, and Dicer to silence viral dsRNA in infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018665      PMCID: PMC2806767          DOI: 10.1073/pnas.0910547107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

2.  Update: filovirus infections among persons with occupational exposure to nonhuman primates.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-04-27       Impact factor: 17.586

3.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Structure of the mouse Stat 3/5 locus: evolution from Drosophila to zebrafish to mouse.

Authors:  K Miyoshi; Y Cui; G Riedlinger; P Robinson; J Lehoczky; L Zon; T Oka; K Dewar; L Hennighausen
Journal:  Genomics       Date:  2001-01-15       Impact factor: 5.736

5.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Authors:  Amy L Hartman; Jason E Dover; Jonathan S Towner; Stuart T Nichol
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein.

Authors:  St Patrick Reid; Washington B Cárdenas; Christopher F Basler
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

7.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

8.  Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.

Authors:  Jonathan S Towner; Pierre E Rollin; Daniel G Bausch; Anthony Sanchez; Sharon M Crary; Martin Vincent; William F Lee; Christina F Spiropoulou; Thomas G Ksiazek; Mathew Lukwiya; Felix Kaducu; Robert Downing; Stuart T Nichol
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.

Authors:  Tsung-Hsien Chang; Toru Kubota; Mayumi Matsuoka; Steven Jones; Steven B Bradfute; Mike Bray; Keiko Ozato
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  73 in total

1.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

3.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

4.  Ebolavirus polymerase uses an unconventional genome replication mechanism.

Authors:  Laure R Deflubé; Tessa N Cressey; Adam J Hume; Judith Olejnik; Elaine Haddock; Friederike Feldmann; Hideki Ebihara; Rachel Fearns; Elke Mühlberger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-08       Impact factor: 11.205

5.  Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist.

Authors:  Daniela Niemeyer; Thomas Zillinger; Doreen Muth; Florian Zielecki; Gabor Horvath; Tasnim Suliman; Winfried Barchet; Friedemann Weber; Christian Drosten; Marcel A Müller
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

6.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

7.  Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Authors:  Shridhar Bale; Jean-Philippe Julien; Zachary A Bornholdt; Alexander S Krois; Ian A Wilson; Erica Ollmann Saphire
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

8.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

9.  Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression.

Authors:  Kathryn M Hastie; Christopher R Kimberlin; Michelle A Zandonatti; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

10.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.